KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to $1.3 million.

  • CRISPR Therapeutics AG's Current Deferred Revenue fell 7111.31% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 7111.31%. This contributed to the annual value of $3.8 million for FY2024, which is 6873.98% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's Current Deferred Revenue stood at $1.3 million, which was down 7111.31% from $2.1 million recorded in Q2 2025.
  • CRISPR Therapeutics AG's Current Deferred Revenue's 5-year high stood at $12.3 million during Q4 2021, with a 5-year trough of $1.3 million in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median Current Deferred Revenue value was $3.7 million (recorded in 2023), while the average stood at $5.0 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Current Deferred Revenue skyrocketed by 17285.9% in 2021 and then crashed by 7111.31% in 2025.
  • CRISPR Therapeutics AG's Current Deferred Revenue (Quarter) stood at $12.3 million in 2021, then changed by 0.0% to $12.3 million in 2022, then changed by 0.0% to $12.3 million in 2023, then plummeted by 68.74% to $3.8 million in 2024, then plummeted by 66.32% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.1 million for Q2 2025, and $3.0 million during Q1 2025.